| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
EGFRvIII (epidermal growth factor receptor class III variant); peptide serves as a tumor-specific neoantigen, presented by MHC class I and II complexes to elicit CD4+ and CD8+ T-cell responses.
|
|---|---|
| ln Vitro |
Not applicable; PEPvIII has no direct enzymatic or receptor-binding activity; it functions as an immunogen. In vitro, dendritic cells (DCs) pulsed with PEPvIII sensitize CD4+ and CD8+ T cells to precisely target and eradicate EGFRvIII-expressing glioma cells.
|
| ln Vivo |
In vivo, PEPvIII in combination with adjuvant (e.g., GM-CSF) elicits a potent humoral and cellular immune response specifically against cells expressing EGFRvIII. In Phase II trials, vaccinated GBM patients with minimal residual disease showed increased progression-free survival (PFS).
|
| Enzyme Assay |
Not applicable; the peptide is not evaluated in enzyme/receptor binding assays. It is presented by MHC molecules on antigen-presenting cells; peptide-MHC complex binding affinity can be measured by surface plasmon resonance (SPR) or by T cell activation assays.
|
| Cell Assay |
Dendritic cells (DCs) are pulsed with PEPvIII (10-100 microg/mL) for 2-4 h; DCs are then co-cultured with autologous CD4+ and CD8+ T cells for 7-10 days; T cell activation is assessed by IFN-gamma ELISpot, intracellular cytokine staining, or proliferation assays.
|
| Animal Protocol |
Mice bearing EGFRvIII-expressing glioma xenografts or patients with newly diagnosed GBM: PEPvIII (50-100 microg) is administered intradermally or subcutaneously with GM-CSF adjuvant on days 1, 2, 3, 8, 15, 22, 29, and 36. Immune responses are assessed by antibody titers (ELISA) and T cell responses (IFN-gamma ELISpot).
|
| ADME/Pharmacokinetics |
Not applicable for the peptide as an active immunotherapy. It is not intended to be quantified as a drug but rather to induce an immune response.
|
| Toxicity/Toxicokinetics |
No toxicity data for PEPvIII TFA; the peptide vaccine has been safe and immunogenic in clinical trials. Common adverse effects include injection site reactions, fatigue, and mild flu-like symptoms. No serious autoimmune toxicity reported.
|
| References | |
| Additional Infomation |
The EGFRvIII peptide vaccine (Rindopepimut/CDX-110) has been evaluated in Phase I, II, and III clinical trials for glioblastoma multiforme. Phase III trial (ACT IV) did not meet its primary endpoint. It is not FDA-approved; available for research use only.
|
| Molecular Formula |
C72H112F3N19O26S
|
|---|---|
| Molecular Weight |
1748.83
|
| Related CAS # |
EGFRvIII peptide (PEPvIII);129112-17-0
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5718 mL | 2.8591 mL | 5.7181 mL | |
| 5 mM | 0.1144 mL | 0.5718 mL | 1.1436 mL | |
| 10 mM | 0.0572 mL | 0.2859 mL | 0.5718 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
